Kiniksa Pharmaceuticals International Plc (KNSA)

$KNSA really digging this move today! Finally time to put $30 in the rearview??

$KNSA taking out the earnings highs from a few days ago. Really strong today in this ugly tape. Calls up to about $3.70 now Guy in the comments was arguing with me about how they were selling them lol. Careful who you follow.

$KNSA With record earnings, a growing pipeline, and analysts upgrading targets, Kiniksa may be on the verge of a massive rally in 2025. https://biotechhealthx.com/biotech-news/kiniksa-pharmaceuticals-knsa-is-breaking-out/

$KNSA Kiniksa $KNSA 🇺🇸 • Q2 revenue: $156.8M (+52%) • Q2 OpEx: $136.6M • Cash: $307.8M • 3,475 active prescribers 🔬 Phase 2/3 trial for KPL‑387 (pericarditis) underway 🗓️ Data expected in 2026 https://investors.kiniksa.com/news-events/press-releases/

$KNSA - Kiniksa Pharmaceuticals International plc Class A Ordinary Shares - 10Q - Updated Risk Factors Kiniksa’s 2025 10-Q highlights heightened risks from reliance on specialty pharmacies, complex global pricing and regulatory hurdles, clinical trial uncertainties, supply chain and manufacturing transitions, intensified competition, expanded IP litigation exposure, evolving healthcare laws, cybersecurity threats, ESG and climate impacts, key personnel retention challenges, and shareholder concentration risks—all potentially impacting financial and operational outcomes. #SpecialtyPharmacies #ShareholderConcentration #KeyPersonnelRetention #ESGImpact #CybersecurityThreats #HealthcareLaws #IPLitigation #SupplyChainTransition #ClinicalTrialRisks #RegulatoryChallenges 🟢 Added 🟠 Removed https://d-risk.ai/KNSA/10-Q/2025-07-29

$KNSA "Heads up alert! Upcoming earnings on Tuesday, 7/29/2025 for $KNSA Bullish (8.4) --- Kiniksa Pharmaceuticals International, plc (KNSA) Financial Analysis Kiniksa Pharmaceuticals has recently demonstrated robust financial performance, significantly exceeding market expectations in its latest earnings release. The company reported a remarkable earnings surprise of +27.78%, and revenue surpassed forecasts by +7.92% for the quarter ending June 2025. The net product revenue for ARCALYST® (rilonacept) showed an impressive 52% year-over-year growth, reaching $156.8 million, and the company raised its projected net product revenue for 2025 to between $625 and $640 million. This strong financial showing has been driven by strategic portfolio execution and successful market penetration of its products. Kiniksa's financial health is further underscored by a significant increase in its cash balance by $39.4 million, bringing it to a total of $307.8 million. This bolstered cash position provides the company with enhanced financial flexibility to fund ongoing clinical trials and potential expansions. The initiation of the KPL-387 Phase 2/3 clinical trial in recurrent pericarditis and the anticipated Phase 2 data in the second half of 2026 are key milestones that could drive future growth. Compared to industry peers, Kiniksa's growth trajectory appears favorable, with a focus on novel therapeutic solutions making it a notable player in the biotech sector. Upcoming Earnings Reports Kiniksa Pharmaceuticals is poised to continue its upward trajectory with its upcoming financial disclosures. The company is expected to sustain its momentum with a focus on both revenue growth and strategic investments in clinical trials. Historically, Kiniksa has shown a pattern of outperforming analyst estimates, and the current market sentiment reflects confidence in its ability to maintain this trend. Analyst consensus estimates suggest continued growth in earnings per share (EPS) and revenue, driven by expanding product lines and strategic partnerships. The potential impact on the stock is positive, with expectations of sustained investor confidence and share price appreciation. Sector Performance Kiniksa operates within the biotechnology sector, which has been experiencing varying levels of performance due to macroeconomic factors and regulatory changes. Overall, the sector has shown resilience, with a strong emphasis on innovation and development of cutting-edge treatments. Biotech companies with solid pipelines and successful product launches, like Kiniksa, are particularly well-positioned to capitalize on growth opportunities. The sector's performance is expected to remain robust, supported by ongoing advancements in technology and increasing demand for novel medical solutions. - Funds were net buyers of $KNSA during the previous reporting quarter. - Funds with large holdings in $KNSA include: - Rubric Capital Management LP, MV: $75MM. Fund Rank: 84% www.rubriccapital.com - Baker Brothers Advisors LP, MV: $63MM. Fund Rank: 72% - Point72 Asset Management LP, MV: $26MM. New position. Fund Rank: 96% www.point72.com - Parkman Healthcare Partners LLC, MV: $17MM. Fund Rank: 67% www.parkmanhp.com - Soleus Capital , MV: $10MM. New position. Fund Rank: 53% - Last 10 days performance: 5% - Last 30 days performance: 10% - Last 90 days performance: 11% Some of the latest news articles: - Title: Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q2 Earnings and Revenue Estimates Publication Date: 7/29/2025 12:40:02 PM, Source: yahoo URL: https://finance.yahoo.com/news/kiniksa-pharmaceuticals-international-plc-knsa-124002370.html?.tsrc=rss - Title: Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution Publication Date: 7/29/2025 11:30:00 AM, Source: yahoo URL: https://finance.yahoo.com/news/kiniksa-pharmaceuticals-reports-second-quarter-113000446.html?.tsrc=rss - Title: Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025 Publication Date: 7/24/2025 8:01:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/kiniksa-pharmaceuticals-report-second-quarter-200100799.html?.tsrc=rss - Title: Exploring US High Growth Tech Stocks with Promising Potential Publication Date: 7/16/2025 5:38:11 PM, Source: yahoo URL: https://finance.yahoo.com/news/exploring-us-high-growth-tech-173811927.html?.tsrc=rss Follow us on stocktwits.com and Substack (chessgmstocks.substack.com). Not a financial advice. Not a trading signal."

Jefferies has updated their rating for Kiniksa Pharmaceuticals ( $KNSA ) to Buy with a price target of 54.

$KNSA pt 33

$KNSA Someone sold a bunch of calls at the 30 strike for 80 days.

Jefferies⬆️ $KNSA PT to $54 from $45 & reiterated at a Buy after they caught up w/ mgmt. following $KNSA's 2Q25 earnings print. $REGN $AMGN $NVS Jefferies said in its note, "Q2 carries over the success in Q1 with another 'beat & raise' - 2025FY guidance increased from previous $590-605M to $625-640M, supported by growth in new/ repeat Rxers, average DoT and penetration into both target 2+ RP and first RP pop. Monthly KLP-387 dev on track, aiming for '28-29 launch. Co has $308M cash/ expects to remain cash flow positive on annual basis. We raise our PT to $54 from previous $45."